These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21420447)

  • 1. Sensitivity of Francisella tularensis to ultrapure water and deoxycholate: implications for bacterial intracellular growth assay in macrophages.
    Chalabaev S; Anderson CA; Onderdonk AB; Kasper DL
    J Microbiol Methods; 2011 Jun; 85(3):230-2. PubMed ID: 21420447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzimidazole-based antibacterial agents against Francisella tularensis.
    Kumar K; Awasthi D; Lee SY; Cummings JE; Knudson SE; Slayden RA; Ojima I
    Bioorg Med Chem; 2013 Jun; 21(11):3318-26. PubMed ID: 23623254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azithromycin effectiveness against intracellular infections of Francisella.
    Ahmad S; Hunter L; Qin A; Mann BJ; van Hoek ML
    BMC Microbiol; 2010 Apr; 10():123. PubMed ID: 20416090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of Ribosome Rescue Arrest Growth of Francisella tularensis at All Stages of Intracellular Replication.
    Goralski TD; Dewan KK; Alumasa JN; Avanzato V; Place DE; Markley RL; Katkere B; Rabadi SM; Bakshi CS; Keiler KC; Kirimanjeswara GS
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3276-82. PubMed ID: 26953190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disulfiram, an alcohol dependence therapy, can inhibit the in vitro growth of Francisella tularensis.
    Hamblin KA; Flick-Smith H; Barnes KB; Pereira-Leal JB; Surkont J; Hampson R; Atkins HS; Harding SV
    Int J Antimicrob Agents; 2019 Jul; 54(1):85-88. PubMed ID: 31029736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OpiA, a Type Six Secretion System Substrate, Localizes to the Cell Pole and Plays a Role in Bacterial Growth and Viability in
    Cantlay S; Haggerty K; Horzempa J
    J Bacteriol; 2020 Jun; 202(14):. PubMed ID: 32366588
    [No Abstract]   [Full Text] [Related]  

  • 7.
    Heine HS; Miller L; Halasohoris S; Purcell BK
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674048
    [No Abstract]   [Full Text] [Related]  

  • 8. Bactericidal activities of antibiotics against intracellular Francisella tularensis.
    Maurin M; Mersali NF; Raoult D
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3428-31. PubMed ID: 11083651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sensitivity of Hungarian strains of Francisella tularensis to antibiotics].
    Füzi M; Kemenes F
    Orv Hetil; 1972 Aug; 113(35):2103-5. PubMed ID: 5051095
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid countermeasure discovery against Francisella tularensis based on a metabolic network reconstruction.
    Chaudhury S; Abdulhameed MD; Singh N; Tawa GJ; D'haeseleer PM; Zemla AT; Navid A; Zhou CE; Franklin MC; Cheung J; Rudolph MJ; Love J; Graf JF; Rozak DA; Dankmeyer JL; Amemiya K; Daefler S; Wallqvist A
    PLoS One; 2013; 8(5):e63369. PubMed ID: 23704901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular localization of Brucella abortus and Francisella tularensis in primary murine macrophages.
    Celli J
    Methods Mol Biol; 2008; 431():133-45. PubMed ID: 18287753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis and Burkholderia pseudomallei.
    Abdelbaqi S; Deslouches B; Steckbeck J; Montelaro R; Reed DS
    J Med Microbiol; 2016 Feb; 65(2):188-194. PubMed ID: 26673248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of TolC Orthologs to
    Kopping EJ; Doyle CR; Sampath V; Thanassi DG
    Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670554
    [No Abstract]   [Full Text] [Related]  

  • 14. [Sensitivity spectrum of Francisella tularensis to antibiotics and synthetic antibacterial drugs].
    Vasi'lev NT; Oborin VA; Vasi'lev PG; Glushkova OV; Kravets ID; Levchuk BA
    Antibiot Khimioter; 1989 Sep; 34(9):662-5. PubMed ID: 2610533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of Therapeutic Compounds.
    Jayamani E; Tharmalingam N; Rajamuthiah R; Coleman JJ; Kim W; Okoli I; Hernandez AM; Lee K; Nau GJ; Ausubel FM; Mylonakis E
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652232
    [No Abstract]   [Full Text] [Related]  

  • 16. A new dye uptake assay to test the activity of antibiotics against intracellular Francisella tularensis.
    Sutera V; Caspar Y; Boisset S; Maurin M
    Front Cell Infect Microbiol; 2014; 4():36. PubMed ID: 24672776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain.
    Aperis G; Fuchs BB; Anderson CA; Warner JE; Calderwood SB; Mylonakis E
    Microbes Infect; 2007 May; 9(6):729-34. PubMed ID: 17400503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of methionine sulfoxide reductase B (MsrB) to Francisella tularensis infection in mice.
    Saha SS; Hashino M; Suzuki J; Uda A; Watanabe K; Shimizu T; Watarai M
    FEMS Microbiol Lett; 2017 Jan; 364(2):. PubMed ID: 28108583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular survival mechanisms of Francisella tularensis, a stealth pathogen.
    Sjöstedt A
    Microbes Infect; 2006 Feb; 8(2):561-7. PubMed ID: 16239121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Francisella tularensis LVS infection of macrophages results in a reduced inflammatory response: evaluation of a therapeutic strategy for intracellular bacteria.
    D'Elia R; Jenner DC; Laws TR; Stokes MG; Jackson MC; Essex-Lopresti AE; Atkins HS
    FEMS Immunol Med Microbiol; 2011 Aug; 62(3):348-61. PubMed ID: 21569124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.